As Drug Shortages Linger, Attention Turns to TPN Crisis
This article was originally published in The Gold Sheet
Executive Summary
The good news is that the number of new drug shortages went down in 2012; the bad news is that the total number of drugs in active shortages is increasing while growing capacity problems are being reported – and shortages of injectable nutrition drugs are especially acute. An FDA economist proposes that rewarding manufacturers for quality may help to alleviate the shortage crisis.
You may also be interested in...
Code Cart Crisis: Anatomy Of An Emergency Drug Shortage
How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.